Delving into the Latest Updates on Emfilermin with Synapse

Overview

Basic Info

Drug Type

Growth factors

Synonyms

LIF, Recombinant LIF protein, rhLIF

+ [2]

Target

LIF

Mechanism

LIF stimulants(Leukemia inhibitory factor stimulants)

Therapeutic Areas

Nervous System DiseasesUrogenital DiseasesEndocrinology and Metabolic Disease+ [2]

Active Indication-

Inactive Indication

Amyotrophic Lateral SclerosisImplantation complicationInfertility+ [3]

Originator Organization

The Walter & Eliza Hall Institute of Medical Research

Active Organization-

Inactive Organization

Merck KGaACSL Innovation Pty Ltd.Merck Serono SA

+ [2]

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 104598

Source: *****

The primary objective of the study was to provide further clinical and statistical evidence of the efficacy of r-hLIF, in comparison with placebo, administered during the luteal phase after IVF and ET for improving embryo implantation in infertile women with a history of at least 2 implantation failures following transfer of fresh embryos. The secondary objective of the study was to assess the safety profile of r-hLIF in the proposed indication.

Start Date01 Apr 2003

Sponsor / Collaborator

Merck KGaA

NCT00504530 / CompletedPhase 1/2

A Randomised, Double-blind, Placebo Controlled, Proof of Concept Study to Assess the Efficacy, Safety and Acceptability of r-hLIF for Improving Embryo Implantation Following in Vitro Fertilisation (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure.

This study was designed to obtain pilot clinical evidence of the efficacy, safety and acceptability of r-hLIF administered during the luteal phase after IVF/intra-cytoplasmic sperm injection (ICSI) and ET for improving embryo implantation in infertile women with a history of at least three implantation failures following ART. Based on LIF expression patterns and experimental data from animal research a role of LIF in embryo implantation is anticipated.

Start Date01 Sep 2001

Sponsor / Collaborator

Merck KGaA

100 Clinical Results associated with Emfilermin

Login to view more data

100 Translational Medicine associated with Emfilermin

Login to view more data

100 Patents (Medical) associated with Emfilermin

Login to view more data

377

Literatures (Medical) associated with Emfilermin

01 Aug 2024·Current Medicinal Chemistry

Leukemia Inhibitory Factor Protects against Degeneration of Cone Photoreceptors Caused by RPE65 Deficiency

Article

Author: Zhang, Houbin ; Dong, Shuqian ; Zhen, Fangyuan ; Wu, Jiahui ; Zhou, Yongwei ; Zou, Tongdan ; Wang, Ting

Background::Retinal pigment epithelium (RPE) 65 is a key enzyme in the visual cycle involved in the regeneration of 11-cis-retinal. Mutations in the human RPE65 gene cause Leber’s congenital amaurosis (LCA), a severe form of an inherited retinal disorder. Animal models carrying Rpe65 mutations develop early-onset retinal degeneration. In particular, the cones degenerate faster than the rods. To date, gene therapy has been used successfully to treat RPE65-associated retinal disorders. However, gene therapy does not completely prevent progressive retinal degeneration in patients, possibly due to the vulnerability of cones in these patients. In the present study, we tested whether leukemia inhibitory factor (LIF), a trophic factor, protects cones in rd12 mice harboring a nonsense mutation in Rpe65.Methods::LIF was administered to rd12 mice by intravitreal microinjection. Apoptosis of retinal cells was analyzed by TUNEL assay. The degeneration of cone cells was evaluated by immunostaining of retinal sections and retinal flat-mounts. Signaling proteins regulated by LIF in the retinal and cultured cells were determined by immunoblotting.Results::Intravitreal administration of LIF activated the STAT3 signaling pathway, thereby inhibiting photoreceptor apoptosis and preserving cones in rd12 mice. Niclosamide (NCL), an inhibitor of STAT3 signaling, effectively blocked STAT3 signaling and autophagy in cultured 661W cells treated with LIF. Co-administration of LIF with NCL to rd12 mice abolished the protective effect of LIF, suggesting that STAT3 signaling and autophagy mediate the protection.Conclusion::LIF is a potent factor that protects cones in rd12 mice. This finding implies that LIF can be used in combination with gene therapy to achieve better therapeutic outcomes for patients with RPE65-associated LCA.

01 Jul 2024·Small

Construction of Inorganic/Polymer Tandem Layer on Li Metal with Long‐Term Stability by LiNO₃ Concentration Gradient Electrolyte

Article

Author: Zhou, Yamei ; Guo, Zhijie ; Chen, Silei ; Feng, Yunchong ; Shi, Yue ; Liu, Xiao ; Zhao, Yong ; Song, Xiaosheng ; He, Jinling ; Chen, Zhonghui ; Zhang, Qi ; Liu, Zewen ; Zhu, Xuebing

AbstractMetal electrode with long cycle life is decisive for the actual use of metal rechargeable batteries, while the dendrite growth and side reaction limit their cyclic stability. Herein, the construction of polymer and inorganic‐rich SEI tandem layer structure on Li metal can be used for extraordinarily extending its cycle life is reported, which is generated by an in situ PVDF/LiF/LiNO3 (PLL) gel layer on the surface of Li metal with a chemically compatible ether solvent. The cycle life of Li//Li cells with the tandem layer structure is over 6000 h, six times longer than those with LiNO3 homogeneous electrolyte. It highlights the importance of LiNO3 concentration gradient electrolyte formed by the in situ PLL gel layer, in which highly concentrated LiNO3 is confined on the surface of Li metal to generate the uniform and inorganic‐rich LiF/Li2O/Li3N layer on the bottom of PVDF/LiF with good mechanical strength, resulting in the dendrite free anode in cell cycling. The assembled Li//LiFePO4 and Li//NMC811 batteries show the capacity retention rate of 80.9% after 800 cycles and 82.3% after 500 cycles, respectively, much higher than those of references.

01 Jun 2024·Journal of Spine Surgery

Lateral interbody fusion for adjacent segment disease: a narrative review

Review

Author: Antonacci, Christopher L ; Zeng, Francine ; Esmende, Sean M ; Patel, Seema M ; Jackson, Casey ; Wellington, Ian J

Background and ObjectiveAdjacent segment disease (ASD) is a late complication of lumbar fusion characterized by persistent symptoms correlating to radiographic changes in the levels immediately above or below the prior fusion. Lateral interbody fusion (LIF) through a direct lateral approach is a minimally invasive and effective surgical treatment for ASD. Biomechanically, LIF for ASD provides significantly decreased motion in multiple planes. While hardware failure and injury to the lumbar plexus are potential complications, these risks may be outweighed by decreased blood loss, shorter operating room (OR) times, and possibly superior patient reported visual analog scale (VAS) scores compared to traditional posterior spinal fusion (PSF) alone. The purpose of this review is to summarize the history, uses, outcomes, and future directions of LIF for ASD.MethodsA review of national databases (PubMed and SCOPUS) was performed using literature from 1900 to 2022. Keywords included terms "LATERAL" and "LUMBAR" and "INTERBODY" and "FUSION" and "ADJACENT" and "SEGMENT" and "DISEASE". Studies that aimed to describe the biomechanical, clinical course and complications, radiological outcomes, biomechanical aspects, need for revision surgery, and/or patient reported outcomes of the XLIF/LIF technique were included.Key Content and FindingsThis review includes a brief overview of the natural history of ASD and current approaches to address it. It then summarizes the main indications and utilization of LIF to address ASD, summarizing reported outcomes in regard to biomechanical, clinical, and radiographic outcomes.ConclusionsLIF has emerged as a minimally invasive and effective surgical treatment for ASD. This mini-review suggests that LIF provides a solid foundational biomechanical construct that has been paired with good patient-reported, clinical, and radiographic outcomes. While further research is required, current literature suggests that LIF for ASD results in fewer complications, decreased morbidity, and decreased need for subsequent surgery compared to other commonly utilized techniques.

100 Deals associated with Emfilermin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB06562

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infertility	Phase 2	-	The Walter & Eliza Hall Institute of Medical Research	-
Infertility	Phase 2	-	Zenyth Advisors LLC	-
Infertility	Phase 2	-	Merck Serono SA	-
Infertility, Female	Phase 2	CH	-	-
Infertility, Female	Phase 2	CH	-	-
Neuromuscular Diseases	Phase 2	AU	-	-
Neuromuscular Diseases	Phase 2	-	Merck Serono SA	-
Neuromuscular Diseases	Phase 2	US	-	-
Neuromuscular Diseases	Phase 2	-	The Walter & Eliza Hall Institute of Medical Research	-
Neuromuscular Diseases	Phase 2	-	Zenyth Advisors LLC	-